Published by Ministry of Health, Labour and Welfare Translated by Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this

English translation, the former shall prevail.

## **Revision of Precautions**

## Isopropylantipyrine/acetaminophen/allylisopropylacetylurea/

## anhydrous caffeine/ethenzamide

February 25, 2021

Therapeutic category Antipyretics, analgesics and anti-inflammatory agents

**(** )

Non-proprietary name Isopropylantipyrine/acetaminophen/allylisopropylacetylurea/anhydrous caffeine/ethenzamide

**Safety measure** Precautions should be revised in the package insert.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>

Pharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instruc	tions): Revised language is underlined
Current	Revision
Use during Pregnancy, Delivery or Lactation	Use during Pregnancy, Delivery or Lactation
This drug should be administered to pregnant women or women	This drug should be administered to pregnant women or women
who may be pregnant only when the therapeutic benefits are	who may be pregnant only when the therapeutic benefits are
considered to outweigh the risks.	considered to outweigh the risks. If such administration is deemed
	necessary, caution should be exercised such as limiting to the
	minimum effective use and monitoring amniotic fluid as necessary.
	Renal impairment and decreased urine output in foetuses as well
	as accompanying oligohydramnios have been reported following
	use of cyclooxygenase inhibitors (oral dosage form or suppository)
	in pregnant women.

Revision in line with the Instructions for Package Inserts of Prescription Drugs, PAB Notification No. 606 by the Director General ofPharmaceutical Affairs Bureau, MHW, dated April 25, 1997 (Old instructions):Revised language is underlined.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan E-mail: <u>safety.info@pmda.go.jp</u>